الفهرس 
Pharmaceutical study on certain drug used in traumatic brain injury
ContentOnly 14 pages are availabe for public view
 |  | from | 333 |  |  |
| | | from | 333 | | |
Abstract
Traumatic brain injury is now the commonest cause of death in subjects under the age of 40. It is described as head injury which refers to any insult to the head region, fractures of the skull and facial bones, intracranial injuries, and injures to the special senses. It is an important cause of injury related to hospitalization, disability and death worldwide, which deserves special attention due to the individual, family and social consequences. Recent clinical study indicated improved outcomes from brain trauma by enhancing the cholinergic function with acetylcholinesterase inhibitors mainly galantamine, as the defective brain functions in TBI (regulation of vigilance, attention and memory) are partly cholinergically mediated. Galantamine is a reversible acetylcholinesterase (AChE) inhibitor, currently approved for the symptomatic treatment of alzheimer disease (AD). It has less adverse effects than other cholinesterase inhibitors due to its selectivity for inhibiting AChE and not butyrylcholinesterase (BuChE). Treatment with galantamine offers several benefits in AD, such as the ability of performing instrumental and basic activities of daily living, improving cognition, and reducing caregiver burden. As Patient compliance to AD treatments is low; alternative routes for effective and well-tolerated treatment are of clinical needs. Although various routes of administration, such as intravenous, subcutaneous, intranasal, and transdermal have been experimentally studied, galantamine oral administration is presently the only approved treatment for clinical use